Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update

Immunotherapy. 2019 Feb;11(3):149-153. doi: 10.2217/imt-2018-0167.

Authors

Omar Abdel-Rahman¹, Don Morris¹

Affiliation

¹ Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

PMID: 30730273
DOI: 10.2217/imt-2018-0167

No abstract available

Keywords: NSCLC; immunotherapy; outcome; prognosis; survival.

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Clinical Trials, Phase III as Topic
Humans
Immunotherapy*
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Practice Guidelines as Topic
Prognosis
Programmed Cell Death 1 Receptor / genetics
Programmed Cell Death 1 Receptor / immunology
Treatment Outcome

Substances

Programmed Cell Death 1 Receptor